The Use of IO Doublet in PD-L1-Negative NSCLC

David Carbone

Metastatic EGFRm NSCLC: 1L Therapy Options

University of Colorado Cancer Center

T. Patil

Surgical Management of High-Risk and Locally Advanced Prostate Cancer

Yale Cancer Center

I. Kim

Enhanced Diagnostics in Prostate Cancer: PSA and Beyond in 2024

Penn Medicine Abramson Cancer Center

D. Lee

ESMO 2024 Summary: Management of Oligoprogressive Disease - Patients…

2024 ESMO Annual Meeting Insights Hub

R. Van den Begin

ESMO 2024 Summary: GU Practice-Changing Trial Results of PEACE-3 (mC…

2024 ESMO Annual Meeting Insights Hub

R. Dreicer

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

AdventHealth

G. Sonpavde

Recent GU Developments and Their Clinical Implications

Insights from 2024 ASCO® GU Annual Meeting

T. Powles, B. Rini

Lazertinib in 1L EGFR-Mutant NSCLC: Unique Mechanism and Benefits of…

Mariam Alexander

Multidisciplinary Panel Discussion: New Treatment Options for Surgic…

David Carbone

B. Stiles

ASCO® GU 2024 Summary: "Important Prostate Cancer Take-Home Messages"

Insights from 2024 ASCO® GU Annual Meeting

E. Efstathiou

Advances in Prostate Cancer Surgery

Penn Medicine Abramson Cancer Center

B. Schurhamer, T. Guzzo

2024 Intervention Selection & Sequencing in Early Stage NSCLC

Total Health

J. Porter

ASCO® 2024 Lung Cancer Highlights: Top Abstracts Including BEAT-SC, …

2024 ASCO® Annual Meeting Insights Hub

B. Halmos

Avoiding Unnecessary Operations in Prostate Cancer

Penn Medicine Abramson Cancer Center

P. Pierorazio

Mediastinal Staging of Lung Cancer

MI&T Congressi

R. Trisolini

Year in Review 2024 - NSCLC Perioperative Therapy

Oncology 2024 Year in Review

B. Halmos

WCLC 2024 Insights: MARIPOSA - Amivantamab + Lazertinib vs. Osimerti…

Insights from 2024 WCLC

S. Gadgeel

WCLC 2024 Insights: Adjuvant vs. Neoadjuvant vs. Peri-Operative Ther…

Insights from 2024 WCLC

J. Von Der Thusen

WCLC 2024 Insights: Interstitial Lung Disease and Lung Cancer - How …

Insights from 2024 WCLC

S. Ikeda